Company Filing History:
Years Active: 2022-2024
Title: Kunihiko Morihiro: Innovator in Antisense Oligonucleic Acids
Introduction
Kunihiko Morihiro is a notable inventor based in Suita, Japan. He has made significant contributions to the field of molecular biology, particularly in the development of antisense oligonucleic acids. With a total of two patents to his name, Morihiro's work focuses on reducing hepatotoxicity in therapeutic applications.
Latest Patents
Morihiro's latest patents revolve around antisense oligonucleic acids designed to minimize hepatotoxicity. The first patent describes an antisense oligonucleic acid characterized by a base length of not less than 7 nucleotides (nt) and not more than 30 nt. It specifies that nucleic acid residues of not less than 1 nt and not more than 5 nt from both terminals are 2',4′-bridged nucleic acids. Additionally, it includes 2′,4′-non-bridged nucleic acid residues present between the terminals, with modifications in one or more bases of the non-bridged residues. This innovative approach aims to enhance the safety and efficacy of therapeutic oligonucleotides.
Career Highlights
Morihiro is affiliated with Osaka University, where he continues to advance his research in the field of antisense technology. His work has garnered attention for its potential applications in treating various diseases while minimizing side effects.
Collaborations
Some of Morihiro's notable coworkers include Satoshi Obika and Reiko Waki. Their collaborative efforts contribute to the ongoing research and development in the field of molecular therapeutics.
Conclusion
Kunihiko Morihiro's contributions to the field of antisense oligonucleic acids highlight his innovative approach to reducing hepatotoxicity in therapeutic applications. His work at Osaka University and his patents reflect a commitment to advancing medical science and improving patient outcomes.